Share on StockTwits
 

Stock analysts at Needham & Company lifted their price objective on shares of Chelsea Therapeutics International (NASDAQ:CHTP) to $10.00 in a report issued on Wednesday, Analyst Ratings Network reports. Needham & Company’s target price points to a potential upside of 102.02% from the company’s current price.

A number of other firms have also recently commented on CHTP. Analysts at Roth Capital raised their price target on shares of Chelsea Therapeutics International to $7.00 in a research note on Friday, January 17th. Separately, analysts at Deutsche Bank raised their price target on shares of Chelsea Therapeutics International from $4.00 to $5.00 in a research note on Wednesday, January 15th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Chelsea Therapeutics International to $7.00 in a research note on Wednesday, January 15th. Three investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $8.00.

Shares of Chelsea Therapeutics International (NASDAQ:CHTP) opened at 4.95 on Wednesday. Chelsea Therapeutics International has a 52-week low of $1.17 and a 52-week high of $5.78. The stock’s 50-day moving average is $4.25 and its 200-day moving average is $3.46. The company’s market cap is $350.3 million. Chelsea Therapeutics International also saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 5,352,469 shares, a drop of 32.4% from the January 15th total of 7,912,013 shares. Currently, 7.4% of the company’s stock are short sold. Based on an average daily trading volume, of 5,243,831 shares, the short-interest ratio is presently 1.0 days.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.